Blue Trust Inc’s Allogene Therapeutics ALLO Stock Holding History

Blue Trust Inc’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-441	Closed	-$1K	–	2171
2023 Q4	$1K	Buy	+441	New	+$1.25K	﹤0.01%	2252

Other funds holding ALLO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Blue Trust Inc's ALLO Position: Q1 2024 in Review

Blue Trust Inc sold out of Allogene Therapeutics (ALLO) in Q1 2024, closing a stake of 441 shares — an estimated $1K sold.

Blue Trust Inc first reported a position in ALLO in Q4 2023 and held it in 1 quarter. The position peaked at $1K in Q4 2023. 161 funds tracked by Wall St. Rank hold ALLO as of Q1 2024.

Blue Trust Inc reported no remaining Allogene Therapeutics position as of Q1 2024 after selling out during the quarter.
Blue Trust Inc sold 441 Allogene Therapeutics shares in Q1 2024, an estimated $1K.
Blue Trust Inc first reported a position in Allogene Therapeutics in Q4 2023 and held it in 1 quarter.
Blue Trust Inc's Allogene Therapeutics position peaked at $1K in Q4 2023.
161 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2024.

Based on Blue Trust Inc's 13F filing for Q1 2024, filed 1 May 2024.